期刊文献+

血清学检查在胰腺癌诊断中的作用 被引量:2

Serology Detection's Diagnostic Value in Pancreatic Cancer
在线阅读 下载PDF
导出
摘要 目的 :对 168例住院胰腺癌患者血清检测 ,评价它们在胰腺癌诊断中的作用。方法 :患者在治疗前进行检测CA199、AFP、CEA、CA5 0、CA12 5、AKP、LDH、γ GT ,超过正常标准者为阳性。结果 :65名患者中CA199阳性率 75 4 % ,119名患者中AFP阳性率 3 36% ,113名患者中CEA阳性率 38 9% ,117名患者中AKP阳性率 5 6 4 % ,113名患者中LDH阳性率 35 4 % ,119名患者中γ GT阳性率 5 8 8% ,4 2名患者CA5 0和 6名患者CA12 5的阳性率分别为 5 7 1%和 5 0 0 %。结论 :CA199可作为有价值的胰腺癌诊断指标 ,CA5 0 ,CA12 5 ,γ GT ,AKP可作为辅助参考指标 ,AFP ,LDH在胰腺癌临床诊断中价值不高 。 Objective To study the serum of 168 pancreatic cancer cases who were in-patient,and assess the serum assay's diagnostic value in pancreatic cancer.Methods The patients were detected carbohydrate antigen 199(CA199),alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen50(CA50),carbohydrate antigen125(CA125),alkalin phosphatase(AKP),lactic dehydrogenase(LDH), r-glutamyl-transpeptidase(γ-GT) before treatment.The data which over than the normal standard means positive detection.Results The CA199 positive rate was 75.4% in 65 cases,the AFP positive rate was 3.36% in 119 cases,the CEA positive rate was 38.9% in 113 cases,the AKP positive rate was 56.4% in 117 cases,the LDH positive rate was 35.4% in 113 cases,theγ-GT positive rate was 58.8%,the CA50 and CA125 positive rate were 57.1% and 50.0% in 42 and 6 cases,respectively.Conclusions All of these serum detection show that CA199 determination has a good sensitivity and was the best index in the diagnosis of pancreatic cancer.It was superior to that of the other serum tumor markers currently available.The CA50,CA125,AKP,γ-GT might be helpful for the diagnosis in pancreatic cancer as a assistant.AFP and LDH have no diagnostic value in pancreatic cancer clinically.CEA can't be a routine index in the diagnosis of pancreatic cancer.
出处 《肿瘤防治杂志》 2003年第4期386-387,共2页 China Journal of Cancer Prevention and Treatment
关键词 胰腺肿瘤 诊断 血清学检查 肿瘤标注 生物学 pancreatic neoplasms/diagnosis serologic tests tumor markers,biological
  • 相关文献

参考文献4

二级参考文献6

  • 1[1]Plebani M, Basso D, Navaglia F, et al. Is CA242 really a new tumor marker for pancreatic adenocarcinoma? Oncology, 1995, 52: 19.
  • 2[2]Lundin J, Roberts PJ, Kuusela P, et al. Prognostic significance of serum CA242 in pancreatic cancer. A comparison with CA19-9. Anticancer Res, 1995, 15: 2181.
  • 3[3]Cappelli G, Paladini S, D'Agata A, et al. Tumor markers in the diagnosis of pancreatic cancer. Tumori, 1999, 85(1, Suppl.1): S19.
  • 4[4]Lamerz R. Role of tumor markers, cytogenetics. Ann Oncol, 1999, 10(Suppl.4): 145.
  • 5张太平,赵玉沛.胰腺癌的肿瘤标志物[J].中国实验诊断学,1997,1(3):11-13. 被引量:9
  • 6Dr. Richard C. Montgomery MD,John P. Hoffman MD,Lee B. Riley MD, PhD,Andre Rogatko PhD,John A. Ridge MD, PhD,Burton L. Eisenberg MD. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas[J] 1997,Annals of Surgical Oncology(7):551~556

共引文献86

同被引文献26

  • 1陈培丰,刘鲁明.中药蛇六谷抗癌活性及诱导癌细胞凋亡[J].中国中医基础医学杂志,2000,6(9):30-33. 被引量:30
  • 2[2]Evans DB, Abbruzzess JL, Willett CG. Cancer of the pancreas. In: Devita VT, Hellman S, Rothenberg SA, eds. Principles & Practice of Oncology. 6th ed. Philadephia: Lippincott Raven Publisher, 2001, 1126
  • 3成文武,刘鲁明,尹永祥.202例胰腺癌转移临床分析[J].中华实用医药杂志,2003,3(6):484.
  • 4[13]Liu LM, Wu LC, Lin SY, et al. Therapeutic evaluation on advanced pancreatic cancer treated by integrative chinese and western medicine: Clinical analysis of 56 cases. Chinese Journal of Integrative Medicine, 2003, 9:39 (Oral/Poster Presentation 1st International Conference for Integrative Oncology, November 17- 19, 2004, NewYork, USA).
  • 5[14]Liu Luming, Shen Yehua, Chen Zhen, et al. Clinical evaluation on pancreatic cancer with liver metastasis treated by integrative traditional and western medicine: Analysis of 31 cases.(Oral/Poster Presentation 1st International Conference for Integrative Oncology, November 17 ~ 19, 2004,) NewYork,USA.第二届国际中西医结合、中医肿瘤学术研讨会论文汇编,广州2004,215
  • 6[15]Liu Luming. Comprehensive therapy of pancreatic cancer by integrative traditional and western medicine. Chinese Journal of Integrative Medicine, 2004, 10 (3) :236
  • 7Dalgeish AG. Tumor markers in malignancies CA19-9 is useful in several cancers[J]. BMJ, 2000,321 (7257) : 380.
  • 8Friess H, Kleeff J, Gumbs A, et al. Molecular versus convertional markers in pancreatic cancer [J]. Digestion, 1997,58:557-563.
  • 9Olivera JF, Keith R, Jeronme M, et al. MUC-1 epithelial tumor mucirr based immunity and cancer vaccines[J]. Immun Rev, 1995,145:61-83.
  • 10Banfi G, Zerbi A, Pastori S, et al. Behavior of tumor markers CA19-9, CA195, CAM43, CA242, and TPS in the diagnosis and follor-up of pancreatic cancer[J]. Clin Chem, 1993,39(3) :420-423.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部